Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a simple survey improve End-of-Life conversations for cancer patients?

NCT ID NCT06955468

First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 36 times

Summary

This pilot study tested whether a short survey can help hospitalized patients with advanced lung or gastrointestinal cancers discuss their goals and preferences with their oncologist after leaving the hospital. The survey asks about treatment goals and understanding of the disease, and the results are shared with the care team. The study enrolled 40 patients and measured how often goals-of-care conversations were documented in medical records within 30 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Priming Survey (behavioral intervention)

What this could lead to

If successful, this approach could help ensure cancer patients receive care that matches their personal preferences and goals.

What could go wrong

This is a small pilot study focused on feasibility, not on proving that the intervention improves outcomes. It may not work in larger or more diverse groups.

Conditions

The condition(s) this trial relates to.

Communication digestive system neoplasm lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.